Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TransMedics Group, Inc. Director's Dealing 2022

Dec 16, 2022

31201_dirs_2022-12-16_da5fd4e6-a9c2-4172-b7d9-cb1b4333cd8b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2022-12-14

Reporting Person: DAMME LAURA (VP, Clinical Affairs)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-12-14 Common Stock M 5947 $38.46 Acquired 5947 Direct
2022-12-14 Common Stock S 5947 $62.43 Disposed 0 Direct
2022-12-15 Common Stock M 250 $38.46 Acquired 250 Direct
2022-12-15 Common Stock S 250 $60.02 Disposed 0 Direct
2022-12-15 Common Stock M 4740 $38.46 Acquired 4740 Direct
2022-12-15 Common Stock S 4740 $58.96 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-12-14 Stock Option (Right to Buy) $38.46 M 5947 Disposed 2031-02-24 Common Stock (5947) Direct
2022-12-15 Stock Option (Right to Buy) $38.46 M 250 Disposed 2031-02-24 Common Stock (250) Direct
2022-12-15 Stock Option (Right to Buy) $38.46 M 4740 Disposed 2031-02-24 Common Stock (4740) Direct

Footnotes

F1: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $62.00 to $62.91, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $60.00 to $60.35, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $58.92 to $59.32, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021.